Toronto Dominion Bank Takes Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Toronto Dominion Bank acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 11,000 shares of the company's stock, valued at approximately $900,000.

Other institutional investors also recently modified their holdings of the company. Scientech Research LLC raised its stake in shares of Vaxcyte by 18.5% in the fourth quarter. Scientech Research LLC now owns 15,273 shares of the company's stock worth $1,250,000 after buying an additional 2,385 shares during the period. Rafferty Asset Management LLC grew its holdings in Vaxcyte by 128.6% during the 4th quarter. Rafferty Asset Management LLC now owns 147,436 shares of the company's stock valued at $12,069,000 after buying an additional 82,940 shares in the last quarter. ProShare Advisors LLC boosted its holdings in shares of Vaxcyte by 40.2% in the 4th quarter. ProShare Advisors LLC now owns 40,875 shares of the company's stock worth $3,346,000 after purchasing an additional 11,729 shares during the period. Paradigm Biocapital Advisors LP boosted its holdings in shares of Vaxcyte by 57.3% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company's stock worth $116,469,000 after purchasing an additional 518,255 shares during the period. Finally, Man Group plc lifted its stake in shares of Vaxcyte by 878.8% during the 4th quarter. Man Group plc now owns 142,426 shares of the company's stock worth $11,659,000 after acquiring an additional 127,875 shares during the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the sale, the chief operating officer now owns 154,931 shares of the company's stock, valued at $11,351,794.37. The trade was a 4.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.10% of the company's stock.

Vaxcyte Trading Up 4.8%

Shares of NASDAQ:PCVX traded up $1.52 during trading on Thursday, hitting $32.90. 495,298 shares of the stock were exchanged, compared to its average volume of 1,393,552. The company has a fifty day moving average price of $35.94 and a two-hundred day moving average price of $67.93. The company has a market cap of $4.24 billion, a PE ratio of -7.14 and a beta of 1.27. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the previous year, the business posted ($0.85) earnings per share. Equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on PCVX. Cantor Fitzgerald assumed coverage on Vaxcyte in a research report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Guggenheim reiterated a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Needham & Company LLC reissued a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a report on Tuesday, April 8th. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Finally, Bank of America reduced their price target on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Vaxcyte currently has a consensus rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.